Introducing Awiqli®, the world’s first once-weekly basal insulin for adults with type 2 diabetes1
Prescription Awiqli® is a once-weekly basal insulin that is used along with diet and exercise to control high blood sugar in adults with type 2 diabetes mellitus1
Are you a health care professional?
Get the latest updates on novoMEDLINK™
Create a novoMEDLINK™ account today to be notified about the features of Awiqli®, new resources, and product availability.
Awiqli® FAQs
Awiqli® is pronounced “ah-WIK-lee."
Awiqli® was approved by the FDA on March 26, 2026.1 Read the press release here.
Common side effects may include: hypoglycemia, serious allergic reactions (whole body reactions), reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching, rash, swelling of your hands and feet, and weight gain.1
Awiqli® is expected to be available in pharmacies in the summer of 2026.
Awiqli® will be available in 2 pen sizes. All pens will have the same 700 U/mL concentration.1
Each package will contain 1 single-patient-use FlexTouch® pen.1
The 3-mL FlexTouch® prefilled pen will come with 13 NovoFine® needles.1 The 1.5-mL FlexTouch® prefilled pen will come with 13 NovoFine® needles.1
How long each pen will last will vary depending on each patient’s prescribed weekly dose and the total units in the pen. Awiqli® will come in:
Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze. Do not use Awiqli® if it has been frozen.1
If not in use (unopened), Awiqli® can be stored refrigerated (36 °F-46 °F) until the expiration date or at room temperature (below 86 °F) for up to 12 weeks.1
Once opened, Awiqli® can be stored refrigerated or at room temperature for up to 12 weeks.1
Resources to help support patients who are starting Awiqli® are anticipated to be available when Awiqli® becomes available in pharmacies.
Novo Nordisk is committed to helping patients access the medications they need. Cost and coverage information for Awiqli® will be available when Awiqli® becomes available in pharmacies.
Reference:
Do not share your Awiqli® FlexTouch® pen or needles with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Make sure you use the right type and dose of insulin. Always check the label on your insulin pen before each injection to avoid mix-ups with Awiqli® and other insulin products or injectable medicines used to treat diabetes. If you use another injectable medicine to treat your diabetes, pay close attention to how you select your Awiqli® dosage. The dosage of Awiqli® is different from other injectable medicines used to treat diabetes.
Always make sure that you select the correct dosage of your Awiqli® FlexTouch® pen as prescribed by your healthcare provider, to avoid dosing errors and accidental overdose. People who are blind or have vision problems should not use this pen without help from a person trained to use the pen.
Do not dial the maximum single dosage (700 units) of your Awiqli® FlexTouch® pen, unless prescribed by your healthcare provider.
Do not use a syringe to withdraw Awiqli® from your pen.
Talk to your healthcare provider if you have any questions about how to correctly dose Awiqli® FlexTouch®.
Awiqli® may cause serious side effects that can be life-threatening, including:
Your insulin dose may need to change because of change in level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness
Common side effects may include: hypoglycemia, serious allergic reactions (whole body reactions), reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching, rash, swelling of your hands and feet, and weight gain
Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion
These are not all the possible side effects of Awiqli®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Do not share your Awiqli® FlexTouch® pen or needles with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Make sure you use the right type and dose of insulin. Always check the label on your insulin pen before each injection to avoid mix-ups with Awiqli® and other insulin products or injectable medicines used to treat diabetes. If you use another injectable medicine to treat your diabetes, pay close attention to how you select your Awiqli® dosage. The dosage of Awiqli® is different from other injectable medicines used to treat diabetes.
Always make sure that you select the correct dosage of your Awiqli® FlexTouch® pen as prescribed by your healthcare provider, to avoid dosing errors and accidental overdose. People who are blind or have vision problems should not use this pen without help from a person trained to use the pen.
Do not dial the maximum single dosage (700 units) of your Awiqli® FlexTouch® pen, unless prescribed by your healthcare provider.
Do not use a syringe to withdraw Awiqli® from your pen.
Talk to your healthcare provider if you have any questions about how to correctly dose Awiqli® FlexTouch®.
Do not share your Awiqli® FlexTouch® pen or needles with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Make sure you use the right type and dose of insulin. Always check the label on your insulin pen before each injection to avoid mix-ups with Awiqli® and other insulin products or injectable medicines used to treat diabetes. If you use another injectable medicine to treat your diabetes, pay close attention to how you select your Awiqli® dosage. The dosage of Awiqli® is different from other injectable medicines used to treat diabetes.
Always make sure that you select the correct dosage of your Awiqli® FlexTouch® pen as prescribed by your healthcare provider, to avoid dosing errors and accidental overdose. People who are blind or have vision problems should not use this pen without help from a person trained to use the pen.
Do not dial the maximum single dosage (700 units) of your Awiqli® FlexTouch® pen, unless prescribed by your healthcare provider.
Do not use a syringe to withdraw Awiqli® from your pen.
Talk to your healthcare provider if you have any questions about how to correctly dose Awiqli® FlexTouch®.
Awiqli® may cause serious side effects that can be life-threatening, including:
Your insulin dose may need to change because of change in level of physical activity or exercise, increased stress, change in diet, weight gain or loss, or illness
Common side effects may include: hypoglycemia, serious allergic reactions (whole body reactions), reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching, rash, swelling of your hands and feet, and weight gain
Get emergency medical help if you have trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, or confusion
These are not all the possible side effects of Awiqli®. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.